{
  "ticker": "IONS",
  "company_name": "Ionis Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT00607373",
      "title": "Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders",
      "start_date": "2007-07",
      "completion_date": "2009-03",
      "enrollment": 0,
      "sponsor": "Kastle Therapeutics, LLC"
    },
    {
      "nct_id": "NCT00734240",
      "title": "Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Inflammatory Diseases",
      "start_date": "2008-07",
      "completion_date": "2010-03",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT01885260",
      "title": "Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Type 2 Diabetes Mellitus",
      "start_date": "2013-07",
      "completion_date": "2014-11",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT00048295",
      "title": "Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Crohn's Disease",
      "start_date": "2002-05",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02658175",
      "title": "The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1",
      "start_date": "2015-12-23",
      "completion_date": "2020-01-15",
      "enrollment": 0,
      "sponsor": "Akcea Therapeutics"
    },
    {
      "nct_id": "NCT03165864",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Thalassemia",
      "start_date": "2017-05-09",
      "completion_date": "2018-09-25",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT00281008",
      "title": "Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hypercholesterolemia, Familial",
      "start_date": "2006-02",
      "completion_date": "2007-12",
      "enrollment": 0,
      "sponsor": "Kastle Therapeutics, LLC"
    },
    {
      "nct_id": "NCT03360747",
      "title": "Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1",
      "start_date": "2017-12-21",
      "completion_date": "2018-09-04",
      "enrollment": 0,
      "sponsor": "Akcea Therapeutics"
    },
    {
      "nct_id": "NCT03714776",
      "title": "A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Mild Hypertension",
      "start_date": "2019-01-03",
      "completion_date": "2019-11-13",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT00063414",
      "title": "ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Ulcerative Colitis",
      "start_date": "2002-11-20",
      "completion_date": "2005-03-24",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE3": 12,
      "PHASE1": 8,
      "PHASE2": 22,
      "": 4,
      "PHASE2, PHASE3": 2,
      "PHASE1, PHASE2": 2
    },
    "by_status": {
      "COMPLETED": 36,
      "RECRUITING": 4,
      "TERMINATED": 4,
      "ACTIVE_NOT_RECRUITING": 4,
      "ENROLLING_BY_INVITATION": 1,
      "APPROVED_FOR_MARKETING": 1
    },
    "active_trials": 9,
    "completed_trials": 36,
    "conditions": [
      "Acromegaly",
      "Advanced Solid Tumors",
      "Alexander Disease",
      "Amyloidosis, Hereditary",
      "Amyotrophic Lateral Sclerosis",
      "Angelman Syndrome",
      "Beta Thalassemia Intermedia",
      "Castrate-Resistant Prostate Cancer",
      "Chronic Bronchitis, Chronic Obstructive Pulmonary Disease",
      "Crohn's Disease",
      "Elevated Lipoprotein(a)",
      "End-stage Renal Disease (ESRD)",
      "FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis",
      "Familial Chylomicronemia Syndrome",
      "Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1",
      "Familial Partial Lipodystrophy",
      "Healthy Volunteers",
      "Hepatitis B, Chronic Hepatitis B Atypical",
      "Hepatitis C, Chronic",
      "Hereditary Amyloidosis, Transthyretin-Related",
      "Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",
      "Heterozygous Familial Hypercholesterolemia, Coronary Artery Disease",
      "Huntington's Disease",
      "Hypercholesterolemia",
      "Hypercholesterolemia, Coronary Heart Disease",
      "Hypercholesterolemia, Familial",
      "Hypertension",
      "Hypertriglyceridemia, Cardiovascular Diseases",
      "Inflammatory Diseases",
      "Lafora Disease",
      "Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication &#X7C; Blood or Tissue &#X7C; Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sj\u00f6gren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome",
      "Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders",
      "Mild Hypertension",
      "Multiple System Atrophy",
      "NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic",
      "Paroxysmal Atrial Fibrillation",
      "Pelizaeus-Merzbacher Disease",
      "Phlebotomy Dependent Polycythemia Vera",
      "Thalassemia",
      "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)",
      "Type 2 Diabetes Mellitus",
      "Ulcerative Colitis",
      "Venous Thromboembolism"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:19:10.893144",
    "search_query": "Ionis Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Ionis+Pharmaceuticals,+Inc."
  }
}